Nuria Chic
Grupo de investigación
- Genómica traslacional y terapias dirigidas en tumores sólidos Pre-doctoral researcher (R1)
Publicaciones destacadas
-
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Autores:Referencia: Journal Of The National Cancer Institute 2022. -
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Autores:Referencia: Journal Of Clinical Oncology 2021. -
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Autores:Referencia: Npj Breast Cancer 2021. -
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
Autores:Referencia: Npj Breast Cancer 2021. -
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Autores:Referencia: Clinical Cancer Research 2020. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Autores:Referencia: Lancet Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Autores:Referencia: Breast Cancer Research 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Autores:Referencia: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Autores:Referencia: Nature Communications 2020. -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Autores:Referencia: Frontiers In Oncology 2019.
Proyectos destacados
-
Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama
Financiador: Fundació Clínic per la Recerca Biomèdica (Sede o evento)Duración: 01/02/2020 -
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes
Financiador: Hospital Clinic de Barcelona (Sede o evento)Duración: 02/12/2019